BIOMAT Database Logo BIOMAT Database Logo

Intra-arterial versus intravenous cisplatinum (in addition to systemic Adriamycin and high dose methotrexate) in the neoadjuvant treatment of osteosarcoma of the extremities. results of a randomized study. 1996

G Bacci, and P Ruggieri, and P Picci, and M Mercuri, and A Ferraro, and G Tella, and S Ferrari, and F Bertoni, and A Comandone
Sezione di Chemioterapia dei Tumori Ossei, Istituto Ortopedico Rizzoli, Bologna, Italy.

Intra-arterial (IA) and intravenous (IV) cisplatinum (CDP) were studied in a multiagent regimen of neoadjuvant chemotherapy for osteosarcoma of the extremities. Preoperatively two cycles of high-dose methotrexate (HDMTX) were administered, followed 5 days later by CDP and Adriamycin (ADM). MTX and ADM were administered IV, and CDP was delivered IA or IV. Postoperatively, good responders received 3 more cycles of the same drugs, while poor responders had a longer chemotherapy including ifosfamide. The rate of good histological response to chemotherapy was significantly higher in patients treated intraarterially (78% vs 46%: P < .004), while no significant differences in terms of disease-free survival were observed between patients who received CDP IA and patients who received CDP IV (55% vs 51%). In the IA group, however, there was only one local recurrence vs 5 in the IV group. The IA infusion of CDP is more active on the primary tumor than the IV infusion.

UI MeSH Term Description Entries
D007069 Ifosfamide Positional isomer of CYCLOPHOSPHAMIDE which is active as an alkylating agent and an immunosuppressive agent. Isofosfamide,Isophosphamide,Asta Z 4942,Holoxan,Iphosphamide,Iso-Endoxan,NSC-109,724,NSC-109724,Iso Endoxan,NSC 109,724,NSC 109724,NSC109,724,NSC109724
D007269 Injections, Intra-Arterial Delivery of drugs into an artery. Injections, Intraarterial,Intra-Arterial Injections,Intraarterial Injections,Injection, Intra-Arterial,Injection, Intraarterial,Injections, Intra Arterial,Intra Arterial Injections,Intra-Arterial Injection,Intraarterial Injection
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D008297 Male Males
D008727 Methotrexate An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA. Amethopterin,Methotrexate Hydrate,Methotrexate Sodium,Methotrexate, (D)-Isomer,Methotrexate, (DL)-Isomer,Methotrexate, Dicesium Salt,Methotrexate, Disodium Salt,Methotrexate, Sodium Salt,Mexate,Dicesium Salt Methotrexate,Hydrate, Methotrexate,Sodium, Methotrexate
D001859 Bone Neoplasms Tumors or cancer located in bone tissue or specific BONES. Bone Cancer,Cancer of Bone,Cancer of the Bone,Neoplasms, Bone,Bone Neoplasm,Neoplasm, Bone
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D005121 Extremities The farthest or outermost projections of the body, such as the HAND and FOOT. Limbs,Extremity,Limb
D005260 Female Females

Related Publications

G Bacci, and P Ruggieri, and P Picci, and M Mercuri, and A Ferraro, and G Tella, and S Ferrari, and F Bertoni, and A Comandone
Treatment of primary osteosarcoma with intra-arterial and intravenous high-dose methotrexate.
July 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
G Bacci, and P Ruggieri, and P Picci, and M Mercuri, and A Ferraro, and G Tella, and S Ferrari, and F Bertoni, and A Comandone
Neoadjuvant chemotherapy for osteosarcoma of the extremities. Good response of the primary tumor after preoperative chemotherapy with high-dose methotrexate followed by cisplatinum and adriamycin. Preliminary results.
April 1988, Chemioterapia : international journal of the Mediterranean Society of Chemotherapy,
G Bacci, and P Ruggieri, and P Picci, and M Mercuri, and A Ferraro, and G Tella, and S Ferrari, and F Bertoni, and A Comandone
The importance of dose-intensity in neoadjuvant chemotherapy of osteosarcoma: a retrospective analysis of high-dose methotrexate, cisplatinum and adriamycin used preoperatively.
April 1990, Journal of chemotherapy (Florence, Italy),
G Bacci, and P Ruggieri, and P Picci, and M Mercuri, and A Ferraro, and G Tella, and S Ferrari, and F Bertoni, and A Comandone
Intra-arterial cisplatinum and intravenous adriamycin in the treatment of osteosarcoma and malignant fibrous histiocytoma of bone: early surgical and clinical results.
January 1990, La Chirurgia degli organi di movimento,
G Bacci, and P Ruggieri, and P Picci, and M Mercuri, and A Ferraro, and G Tella, and S Ferrari, and F Bertoni, and A Comandone
The effect of intra-arterial versus intravenous cisplatinum in the neoadjuvant treatment of osteosarcoma of the limbs: the experience at the Rizzoli Institute.
January 1996, La Chirurgia degli organi di movimento,
G Bacci, and P Ruggieri, and P Picci, and M Mercuri, and A Ferraro, and G Tella, and S Ferrari, and F Bertoni, and A Comandone
Neoadjuvant chemotherapy for osteosarcoma of the extremities with synchronous lung metastases: treatment with cisplatin, adriamycin and high dose of methotrexate and ifosfamide.
January 2000, Oncology reports,
G Bacci, and P Ruggieri, and P Picci, and M Mercuri, and A Ferraro, and G Tella, and S Ferrari, and F Bertoni, and A Comandone
Effect of intraarterial versus intravenous cisplatin in addition to systemic doxorubicin, high-dose methotrexate, and ifosfamide on histologic tumor response in osteosarcoma (study COSS-86).
October 1990, Cancer,
G Bacci, and P Ruggieri, and P Picci, and M Mercuri, and A Ferraro, and G Tella, and S Ferrari, and F Bertoni, and A Comandone
Neoadjuvant chemotherapy with high-dose methotrexate in osteosarcoma.
December 2008, The Lancet. Oncology,
G Bacci, and P Ruggieri, and P Picci, and M Mercuri, and A Ferraro, and G Tella, and S Ferrari, and F Bertoni, and A Comandone
High dose ifosfamide in combination with high dose methotrexate, adriamycin and cisplatin in the neoadjuvant treatment of extremity osteosarcoma: preliminary results of an Italian Sarcoma Group/Scandinavian Sarcoma Group pilot study.
April 2002, Journal of chemotherapy (Florence, Italy),
G Bacci, and P Ruggieri, and P Picci, and M Mercuri, and A Ferraro, and G Tella, and S Ferrari, and F Bertoni, and A Comandone
Neoadjuvant chemotherapy for the treatment of osteosarcoma of the extremities: excellent response of the primary tumor to preoperative treatment with methotrexate, cisplatin, adriamycin, and ifosfamide. Preliminary results.
January 1995, La Chirurgia degli organi di movimento,
Copied contents to your clipboard!